Ivosenib Tablets — Ivosidenib 250 mg (60 Tabs) Everest

Prescribed by specialists for adults with a susceptible IDH1 mutation:

• 🔹 Acute Myeloid Leukemia (AML): For relapsed or refractory AML. Also as first-line treatment for patients ≥75 years or those ineligible for intensive chemotherapy.
• 🔹 Cholangiocarcinoma: Previously treated, locally advanced or metastatic bile duct cancer.

Sales Unit: Bottle containing 60 film-coated tablets (250 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

• Standard Dosage: Typically 500 mg (two 250 mg tablets) taken orally once daily at the same time.
• Administration: Swallow whole with water. Do not split, crush, or chew. Can be taken with or without food (avoid high-fat meals).
• Duration: Treatment typically continues as long as the patient derives clinical benefit (at least 6 months recommended for AML).
• ✋ Missed Dose: If missed by more than 12 hours, skip the dose and resume the next day. Do not double up.

• ⛔ Cardiac Issues: Patients with Long QT syndrome or those taking medications that prolong the QT interval.
• Pregnancy and Breastfeeding: Can cause fetal harm.
• Pediatric patients (safety not established).
• Hypersensitivity to Ivosidenib.
• Severe hepatic impairment.

Requires strict medical supervision. Potential side effects include:

• ⚠️ Differentiation Syndrome: A serious, potentially life-threatening condition (symptoms: fever, shortness of breath, rapid weight gain). Requires immediate medical attention.
• ❤️ QTc Prolongation: Changes in heart rhythm visible on ECG.
• 📉 Hematologic: Leukocytosis (high white blood cell count).
• 🤢 General: Fatigue, joint pain (arthralgia), diarrhea, nausea.